Gossamer Bio Stock Price, News & Analysis

Gossamer Bio (NASDAQ: GOSS) reported Q2 2025 financial results and provided updates on its lead drug candidate seralutinib. The company completed enrollment of 390 patients in its Phase 3 PROSERA study for PAH treatment, with topline results expected in February 2026. The study's primary endpoint is change in six-minute walk distance at week 24.

Financial highlights include $212.9 million in cash and equivalents, expected to fund operations into 2027. Q2 revenue was $11.5 million, with a net loss of $38.3 million ($0.17 per share). The company is also preparing to launch the Phase 3 SERANATA study for PH-ILD in Q4 2025, targeting approximately 480 patients.

Gossamer Bio (GOSS) has completed enrollment for its Phase 3 PROSERA study evaluating seralutinib for pulmonary arterial hypertension (PAH) treatment. The study, conducted in collaboration with Chiesi Group, enrolled 390 patients and expects to announce topline results in February 2026. The double-blind, placebo-controlled trial evaluates seralutinib against placebo, with patients receiving treatment for up to 48 weeks. The primary endpoint measures change in six-minute walk distance at week 24. The enrolled patient population shows promising baseline characteristics, with 74% being Functional Class III patients and a mean 6MWD of 374 meters. The study leverages enrichment criteria including REVEAL Lite 2 Risk Score to identify patients more likely to demonstrate significant benefits.

Gossamer Bio (GOSS) has granted non-qualified stock options to three non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The options allow purchase of up to 69,875 shares at $1.26 per share, matching GOSS's closing price on June 5th, 2025. These 10-year options vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment. The grants, approved by the Compensation Committee, serve as employment inducements in compliance with Nasdaq Rule 5635(c)(4). Gossamer Bio is a late-stage biopharmaceutical company developing seralutinib for PAH and PH-ILD treatment.

Gossamer Bio (NASDAQ: GOSS) announced the closure of new patient screening for its Phase 3 PROSERA study evaluating seralutinib in PAH patients. The study has enrolled 343 patients and expects to complete enrollment with over 350 patients in early June 2025. Topline results are expected in February 2026. The company also plans to initiate the Phase 3 SERANATA study in PH-ILD patients in Q4 2025. Financial highlights include cash position of $257.9 million as of March 31, 2025, expected to fund operations into H1 2027. Q1 2025 results showed revenue of $9.9 million from Chiesi collaboration, R&D expenses of $38.0 million, and a net loss of $36.6 million ($0.16 per share).

Gossamer Bio (NASDAQ: GOSS), a late-stage clinical biopharmaceutical company, will release its first quarter 2025 financial results on Thursday, May 15, 2025. The company, which focuses on developing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will host a conference call and webcast at 4:30 p.m. ET on the same day. Management will discuss financial results and provide a corporate update during the call.

Gossamer Bio (GOSS) has granted stock options to three non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase up to 258,750 shares at an exercise price of $1.25 per share, matching GOSS's closing price on May 5, 2025. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment. The grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Gossamer Bio (NASDAQ: GOSS) announced its upcoming presentation at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 16-21, 2025. The company will present a poster titled "Seralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation" on Sunday, May 18th. The presentation focuses on seralutinib, which is being developed in collaboration with the Chiesi Group for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The poster will be available on Gossamer Bio's website after the conference.

Gossamer Bio (Nasdaq: GOSS) has announced the approval of inducement grants under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee of Gossamer's Board of Directors has approved non-qualified stock option awards for one non-executive employee to purchase up to 55,000 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The options, granted on April 7, 2025, have an exercise price of $0.82 per share, matching the closing price of Gossamer's common stock on Nasdaq Global Select Market. The options feature a ten-year term with a four-year vesting schedule: 25% vesting after one year, followed by the remaining balance vesting in 36 monthly installments, contingent on continued employment.

Gossamer Bio (NASDAQ: GOSS) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its pulmonary hypertension drug development programs. The company's lead candidate, seralutinib, is advancing with the PROSERA Phase 3 trial in PAH, with topline data expected in Q4 2025.

Key developments include seralutinib receiving Orphan Drug Designation in Japan for PAH treatment and plans to initiate a registrational Phase 3 trial for PH-ILD in H2 2025. The company ended 2024 with $294.5 million in cash and equivalents, expected to fund operations into H1 2027.

Financial highlights for 2024 include: R&D expenses of $138.5 million (vs $135.3M in 2023), G&A expenses of $36.1 million (vs $38.5M in 2023), and a significantly reduced net loss of $56.5 million or $0.25 per share (compared to $179.8M or $1.18 per share in 2023).